CenterLab’s anti-diabetic drug candidate CS02 meets primary endpoint in phase 2 trial
Taiwanese pharma company Center Laboratories (CenterLab) said that its anti-diabetic drug candidate CS02 has met the primary endpoint of a phase 2 clinical trial. According to Center Laboratories, the orally administered small molecule drug candidate delivered significant reductions in glycated hemoglobin (HbA1c) in comparison to the placebo group. The phase 2 clinical trial is a […]
Irish medical device company Medtronic has secured a $337 million product investment from Blackstone Life Sciences for advancing new, innovative products particularly designed to ease the burden of diabetes management. Through the new capital, Medtronic intends to increase research and development (R&D) funding in its diabetes group by a significant extent besides accelerating its diabetes pump […]
Continue reading …
Mylan and Biocon have secured approval from the US Food and Drug Administration (FDA) for Semglee (insulin glargine injection) in vial and pre-filled pen presentations to regulate high blood sugar in adults with type 2 diabetes and adult and pediatric patients with type 1 diabetes. According to Mylan, Semglee has an identical amino acid sequence […]
Continue reading …
ForaCare Suisse has launched a new cellular multi-functional diabetes monitoring device FORA 6 GTel based on its Lab in the Pocket technology. The Lab in the Pocket technology, which has also been newly launched, is available on the GTel model and FOR A 6 Series products, said the Swiss healthcare technology company. According to ForaCare […]
Continue reading …
Rybelsus FDA approval : Danish pharma company Novo Nordisk has bagged approval from the US Food and Drug Administration (FDA) for Rybelsus (semaglutide) oral tablets for its use in patients with type 2 diabetes. The FDA approval for Rybelsus is to improve control of blood sugar in addition to diet and exercise in adults having […]
Continue reading …Vertex to acquire Semma Therapeutics to advance stem cell-based treatments for type 1 diabetes
September 4, 2019 No Comment
Vertex acquisition of Semma Therapeutics : US biotechnology company Vertex Pharmaceuticals has agreed to acquire privately-held biotechnology company Semma Therapeutics for $950 million in cash, as per the latest pharma acquisition news. Both the pharma companies are based in Massachusetts. Post-acquisition, Vertex Pharmaceuticals will advance curative cell-based treatments of Semma Therapeutics for type 1 diabetes and […]
Continue reading …Boehringer Ingelheim to initiate phase 2 trial of BI 456906 in obesity, diabetes
September 3, 2019 No Comment
German drugmaker Boehringer Ingelheim will initiate Phase 2 clinical trial of dual-acting GLP-1/glucagon agonist BI 456906 in obesity and diabetes in late 2019. The compound in-licensed from Zealand Pharma is derived from the natural gut hormone oxyntomodulin and activates both the GLP-1 and glucagon receptors to control metabolic activities. The dual agonist BI 456906 with […]
Continue reading …Aptar wins FDA approval for Unidose Powder System for nasal spray of hypoglycemia drug
July 26, 2019 No Comment
AptarGroup (Aptar) said that its Unidose Powder System has been approved by the US Food and Drug Administration (FDA) for the intranasal, needle-free rescue treatment drug – Lilly’s Baqsimi nasal powder, which was indicated for the treatment of severe hypoglycemia in people with diabetes. (Read Baqsimi FDA approval) The announcement marks the first approval by […]
Continue reading …
Baqsimi FDA approval : Eli Lilly and Company (Lilly) has secured the US Food and Drug Administration (FDA) approval) for Baqsimi nasal powder for the treatment of severe hypoglycemia in patients with diabetes aged four years and older. According to the FDA, Baqsimi is the first glucagon therapy approved for the emergency treatment of the […]
Continue reading …
Myxredlin FDA approval : US health care company Baxter International has secured approval from the US Food and Drug Administration (FDA) for Myxredlin (Insulin Human in 0.9% Sodium Chloride Injection), a ready-to-use insulin for IV infusion. Myxredlin is approved for use as a short-acting human insulin to enhance glycemic control in adults and pediatric patients […]
Continue reading …
Business News Today
- Dr. Reddy’s reports success for Russian Covid-19 vaccine Sputnik V
- TCS rolls out Autoscape solution suite for autonomous and connected vehicle experiences
- Infosys Q3 2020 results : Indian IT services giant reports $705m net profit
- Safehold Special Risk acquires motorsports insurance firm WSIB Insurance
- OncoSec Medical begins phase 2 OMS-104 melanoma trial with TAVO, OPDIVO combo
- Thoma Bravo-backed Majesco acquires insurtech company ClaimVantage
- Tata Power gets LOA from KSEBL for 110MW solar power project in Kerala
- Albemarle to invest up to $50m to double lithium production at Silver Peak facility
- Westland Insurance acquires Nova Scotia-based Storm Insurance Group
- Indian B2B ecommerce platform udaan bags $280m in new funding round
